View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 17, 2022updated 11 Jul 2022 2:13pm

Algernon receives positive FDA feedback on Phase IIb chronic cough trial

The pre-IND meeting guided the company on the Phase IIb protocol design and selection of trial endpoints.

The US Food and Drug Administration (FDA) has provided positive feedback for Algernon Pharmaceuticals’ Phase IIb clinical trial of NP-120 (ifenprodil) to treat chronic cough. 

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A receptor antagonist of N-methyl-D-aspartate (NMDA), ifenprodil precisely acts on the NMDA-type subunit 2B (GluN2B).

The feedback was provided by the agency at the pre-Investigational New Drug (pre-IND) meeting for the therapy.

The meeting provided guidance on the Phase IIb protocol design submitted by Algernon and the endpoints that were selected, according to an announcement.

Furthermore, the FDA sought completion of standard genotoxicity testing before commencing the trial, which Algernon expects to require nearly 90 days to complete.

The company had requested for the pre-IND meeting to advance the Phase IIb trial of the therapy to treat chronic cough in the US. 

Algernon CEO Christopher Moreau said: “We are very pleased with the response we received from the FDA. 

“We look forward to the final data set from our IPF and chronic cough study so that we can plan our next steps.”

In September last year, the company reported a positive trend in the interim results from the chronic cough portion of a Phase II trial, which is set in Australia and New Zealand and for idiopathic pulmonary fibrosis (IPF) and chronic cough.

The interim assessment analysed 24-hour and waking cough counts recorded with an ambulatory cough monitor at baseline and following treatment with thrice-daily 20mg dose of ifenprodil for four and 12 weeks. 

Results demonstrated a trend to a relative decline in cough count as against the baseline.

Ifenprodil was found to offer a significant decline in cough count and a delay in cough development versus vehicle controls in an acute cough in vivo animal study. 

In September 2020, the Data and Safety Monitoring Board (DSMB) recommended the company to continue its Phase IIb/III trial of Ifenprodil for Covid-19.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena